Nanovaccine achieved tumour inhibition rate of 89.3 per cent when tested on mice with aggressive form of the disease, study finds.

A breakthrough new treatment that is currently being tested successfully on rodents, promises tumour termination with one ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

The change to a single-dose HPV vaccine has led to more girls in Doncaster receiving the jab in the last school year, new figures suggest.

TWO women lose their lives to cervical cancer every day in the UK. Like all types of the disease, the earlier it’s caught, the better. Around 95 per cent of those diagnosed at stage 1 will ...

SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...